Cost Plus Drugs Custom Case Solution & Analysis

Evidence Brief: Mark Cuban Cost Plus Drug Company

1. Financial Metrics

• Pricing Structure: Manufacturing or acquisition cost plus 15 percent markup, 3 dollar pharmacy handling fee, and 5 dollar shipping fee.
• Capital Investment: 11 million dollar investment for a 22000 square foot sterile manufacturing facility in Dallas, Texas.
• Product Scope: Over 1000 generic medications offered at launch.
• Market Context: Pharmacy Benefit Managers (PBMs) control approximately 80 percent of the United States prescription drug market.
• Price Discrepancy: Examples include Imatinib (leukemia drug) priced at 17 dollars through the company versus a 2500 dollar retail price.

2. Operational Facts

• Fulfillment: Initial partnership with Truepill to handle pharmacy operations and home delivery.
• Manufacturing: Construction of a domestic facility to produce drugs categorized as being in short supply or having high price volatility.
• Supply Chain: Direct purchasing from manufacturers to bypass wholesalers and traditional PBM intermediaries.
• Digital Presence: Direct-to-consumer (D2C) online platform requiring patients to request providers send prescriptions directly to the entity.

3. Stakeholder Positions

• Mark Cuban: Lead investor and namesake; positions the brand around radical transparency and public trust.
• Alex Oshmyansky: Founder and CEO; focuses on the ethical imperative to reduce drug costs and eliminate opaque rebates.
• Pharmacy Benefit Managers: Incumbents (CVS Caremark, Express Scripts, OptumRx) who utilize spread pricing and manufacturer rebates.
• Employers: Payers who are increasingly frustrated by rising premiums but are often locked into restrictive PBM contracts.

4. Information Gaps

• Customer Acquisition Cost: Data regarding the cost to acquire a recurring patient versus a one-time purchaser is absent.
• Retention Rates: Information on patient loyalty when their specific medication prices fluctuate or become available through insurance.
• PBM Contractual Barriers: Specific legal penalties for employers who attempt to carve out generic spend from their primary PBM contracts are not detailed.

Strategic Analysis

1. Core Strategic Question

• Can a transparency-driven D2C model achieve sufficient scale to force a structural shift in the US pharmaceutical supply chain?
• How can the company overcome the friction of out-of-pocket payments in an economy built on employer-sponsored insurance?

2. Structural Analysis

The pharmaceutical industry functions as an oligopsony where three PBMs dictate access. The Value Chain analysis reveals that the company removes three layers of cost: wholesaler margins, PBM spread pricing, and retail pharmacy overhead. However, the Jobs-to-be-Done framework suggests patients do not just buy drugs; they buy financial predictability. The current model forces patients to pay 100 percent of the cost upfront, which may not count toward insurance deductibles, creating a psychological barrier to adoption for high-utilization patients.

3. Strategic Options

• Option A: Enterprise B2B Pivot. Transition from a D2C pharmacy to a transparent PBM alternative for self-insured employers.
  Rationale: Aggregates demand through corporations rather than individual marketing.
  Trade-offs: Requires a sophisticated sales force and integration with complex benefits administration software.
• Option B: Vertical Manufacturing Specialist. Focus exclusively on manufacturing drugs that are in shortage or have monopolistic pricing.
  Rationale: Captures higher margins and solves a critical public health issue that PBMs cannot ignore.
  Trade-offs: High capital expenditure and intense regulatory scrutiny from the FDA.

4. Preliminary Recommendation

Pursue Option A. The D2C model is an effective marketing tool but lacks the volume to disrupt the Big Three PBMs. By partnering directly with self-insured employers, the company can bypass the insurance friction and secure predictable, high-volume demand. This path transforms the company from a consumer alternative into a structural necessity for corporate cost containment.

Implementation Roadmap

1. Critical Path

• Month 1-3: Launch a dedicated B2B portal for benefits managers to compare their current PBM spend against the transparent pricing of the company.
• Month 4-6: Complete the Dallas manufacturing facility and secure FDA certification for the first three high-demand sterile injectables.
• Month 7-12: Establish data-sharing agreements with major Third-Party Administrators (TPAs) to ensure out-of-pocket spend on the platform counts toward patient deductibles.

2. Key Constraints

• PBM Exclusivity: Many employers are bound by contracts that penalize them for using outside pharmacies. Success requires legal strategies to challenge these restrictive covenants.
• Consumer Habit: Transitioning patients from their local CVS or Walgreens to an online delivery model requires overcoming the convenience of immediate pickup for acute medications.

3. Risk-Adjusted Implementation Strategy

The primary risk is a price-matching response from incumbent PBMs. To mitigate this, the company must emphasize the permanence of its 15 percent markup model versus the temporary discounts of competitors. The implementation must prioritize chronic medications where long-term savings are visible and recurring, rather than acute treatments where speed outweighs cost. Contingency plans include white-labeling the pricing engine for smaller, independent PBMs who wish to compete with the industry leaders.

Executive Review and BLUF

1. BLUF

The Mark Cuban Cost Plus Drug Company must pivot from a direct-to-consumer pharmacy to an enterprise-grade utility. While the current model provides significant savings on generics, it remains a peripheral solution for most Americans due to its exclusion from the insurance deductible loop. To achieve long-term viability, the company must integrate with self-insured employers and complete its manufacturing facility to insulate itself from wholesaler price volatility. The goal is not to compete with pharmacies but to replace the opaque pricing logic of the pharmaceutical industry with a fixed-margin standard. APPROVED FOR LEADERSHIP REVIEW.

2. Dangerous Assumption

The analysis assumes that price is the primary driver of patient behavior. In reality, the convenience of the retail pharmacy network and the integration of drug costs into a single insurance deductible represent a powerful status quo that low prices alone may not break.

3. Unaddressed Risks

4. Unconsidered Alternative

The team did not evaluate the potential of a hybrid brick-and-mortar strategy. Partnering with a national non-pharmacy retailer (such as Costco or a regional grocery chain) could provide the physical footprint necessary to handle acute prescriptions while maintaining the transparent pricing model.

5. MECE Strategic Pillars

• Direct-to-Consumer: Maintain the brand as the public face of affordable medication.
• Direct-to-Employer: Capture the enterprise market through transparent PBM services.
• Direct-to-Manufacturing: Secure the supply chain for high-risk and high-cost medications.